| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC1757 | Dfkbp-2 | Proteolysis targeting chimeras (PROTAC), potently decreasing FKBP12 abundance in MV4;11 cells, leading to over 80% reduction of FKBP12 at 0.1 μM and 50% reduction at 0.01 μM |
|
| DCC1758 | Dg-051 | Novel potent, orally active inhibitor of LTA4H |
|
| DCC1759 | dgat2 Inhibitor 122 | Selective inhibitor of diacylglycerol acyltransferase 2 (DGAT2) |
|
| DCC1760 | Dg-c8-phip | The major adduct formed by the food-borne carcinogen, PhIP with DNA |
|
| DCC1761 | Dgj-pfpht | Novel human α-galactosidase A ligand, capable of stabilizing α-Gal A and restoring trafficking |
|
| DCC1762 | Dgts(16:0/16:0) | Abundant lipid in the membranes of many algae, lower plants, and fungi, showing an inverse concentration relationship with phosphatidylcholine, being capable of replacing phosphatidylcholine |
|
| DCC1763 | Dgy-08-097 | Novel HCV NS3 degrader, reducing susceptibility to resistance mutations, potently inhibiting HCV in a cellular infection model, exhibiting the most potent degradation (DC50 of 50nM at 4h) of HCV NS3, |
|
| DCC1764 | Dh20931 | Novel growth inhibitor of both triple-positive and triple-negative human breast cancer cell lines |
|
| DCC1765 | Dha-37 | Novel inducer of autophagic cell death through upregulation of HMGB1 in A549 cells |
|
| DCC1766 | Dhpcc-9 | Novel Pim kinase inhibitor |
|
| DCC1767 | Dhpm-93 | The most potent inhibitor of sodium iodide symporter (NIS) reported to date |
|
| DCC1768 | Di-1859 | Novel potent, selective and covalent inhibitor of DCN1, selectively inhibiting neddylation of cullin 3 in cells |
|
| DCC1769 | Diabzi Sting Agonist | Novel STING agonist with enhanced binding to STING and cellular function, displaying strong anti-tumour activity |
|
| DCC1770 | Diabzi Sting Agonist-3 | Novel potent and selective STING agonist, activating secretion of IFNβ, IL-6, TNF, and KC/GROα, exhibiting durable anti-tumour effects |
|
| DCC1771 | Diafluo | Novel probe for protein S-sulfinylation from cells |
|
| DCC1772 | Dianicline | Selective alpha4beta2 nAChR partial agonist for the treatment of nicotine dependence to assist in smoking cessation |
|
| DCC1773 | Diazaborine | Novel Inhibitor of the AAA-ATPase Drg1, blocking ribosome biogenesis |
|
| DCC1774 | Diazoline | Histamine H1-receptor antagonist |
|
| DCC1775 | Dibromo-morin | Morin derivative, enhancing neural glyoxalase pathway (GP) activity and preventing methylglyoxal-mediated oxidative stress (OS) in an AD model |
|
| DCC1776 | Diclofenac Acyl Glucuronide | Major biliary metabolite of Diclofenac, a nonsteroidal antiinflammatory drug and COX inhibitor |
|
| DCC1777 | Diclofenac Potassium | Non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions |
|
| DCC1778 | Diclosulam | Selective herbicide for the control of dicot weeds |
|
| DCC1779 | Did Perchlorate Featured | Lipophilic fluorescent reagent, labeling membranes and other hydrophobic structures |
|
| DCC1780 | Didehydro-cortistatin A | Natural Tat inhibitor, blocking HIV-1 transcription by specifically targeting the viral transactivator, Tat |
|
| DCC1781 | Dids Sodium Salt | Inhibitor of DTDST inhibitor, a novel intestinal epigallocatechin gallate (EGCg) transporter |
|
| DCC1782 | Diethyl Bipy55'dc | Novel inhibitor of CP4H activity in cultured cells at concentrations that do not cause iron deficiency |
|
| DCC1783 | Diethyl Pyimdc | Novel inhibitor of CP4H activity in cultured cells at concentrations that do not cause iron deficiency |
|
| DCC1784 | Diethylcarbamazine Citrate | Muscle relaxant, causing general central nervous system depression, relieving pain caused by strains, sprains, and other musculoskeletal conditions |
|
| DCC1785 | Difenidol | Antiemetic agent used in the treatment of vomiting and vertigo |
|
| DCC1786 | Difeterol | Agonist of the androgen receptor (AR); #333333; font-family: "Helvetica Neue", Helvetica, Arial, sans-serif; font-size: 14px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: |
|
